Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of ZGGS18 in Patients With Advanced Solid Tumors
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors
Official title: A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
222
Start Date
2022-11-15
Completion Date
2026-11-01
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
ZGGS18 for Injection
0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18,intravenous infusion, once every 2 weeks.
ZGGS18 for Injection
Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18,intravenous infusion, once every 2 weeks.
Locations (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, China